Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion

Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research
October 22, 2018

On December, 3, 2018, Engage Therapeutics announced at the American Epilepsy Society’s Annual Meeting the successful completion of the open label portion of the StATES (Staccato Alprazolam Terminates Epileptic Seizures) study. Enrollment will now begin in the double blind, placebo-controlled portion of the study. Results from the open label portion of the study will be presented at a major medical meeting in the first half of 2019. Read the full press release for more information.

Click here to download the press release (PDF)